Amlodipine + Olmesartan Medoxomil
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Tenivasc 5/20 is a fixed-dose combination of Olmesartan Medoxomil and Amlodipine, designed to effectively control high blood pressure. Olmesartan is an angiotensin II receptor blocker (ARB), while Amlodipine is a calcium channel blocker (CCB). Together, they relax blood vessels, reduce vascular resistance, and help the heart pump blood more efficiently, leading to sustained blood pressure reduction.
Amlodipine inhibits calcium entry into vascular smooth muscle and myocardial cells, causing peripheral and coronary vasodilation and improving oxygen delivery to the heart.
Olmesartan Medoxomil selectively blocks angiotensin II (AT₁) receptors, preventing vasoconstriction and aldosterone secretion, thereby lowering blood pressure and improving blood flow.
Management of hypertension to reduce cardiovascular risk
Initial dose: 5 mg/20 mg once daily
Dose adjustment: May be increased after 1–2 weeks based on response
Maximum dose: 10 mg/40 mg per day
Elderly: Consider a lower starting dose
Hepatic impairment: Use with caution in mild to moderate impairment
Can be taken with or without food
Common (>10%)
Peripheral edema
Other Possible Effects
Palpitations
Orthostatic hypotension
Increased urinary frequency or nocturia
Skin reactions (rash, pruritus)
Rare but Serious
Acute renal failure
Enhanced hypotensive effects with other antihypertensives
Increased risk of hyperkalemia with potassium-sparing diuretics, potassium supplements, ACE inhibitors, ciclosporin, or eplerenone
NSAIDs may reduce antihypertensive efficacy and impair renal function
May increase lithium levels and toxicity
Caution when used with clonidine, catecholamine-depleting drugs, or prostaglandin synthesis inhibitors
Category C (1st trimester)
Category D (2nd & 3rd trimesters)
Not recommended during breastfeeding due to the potential risk to the infant
Drugs affecting the renin-angiotensin system may cause fetal injury or death during the 2nd and 3rd trimesters
Discontinue immediately if pregnancy is detected
Risk of symptomatic hypotension in volume- or salt-depleted patients
Monitor renal function and serum potassium, especially in renal impairment
Avoid use in severe renal or hepatic impairment
Use cautiously in patients with aortic or mitral stenosis, hypertrophic cardiomyopathy, or renal artery stenosis
Patients with primary aldosteronism may respond poorly
Do not store above 30°C. Keep away from light and out of the reach of children
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.